Lymphodepletion

Phase 2Small molecule

MMediGene

Lymphodepletion is one of 126 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Lymphodepletion

MMediGene

Phase 2

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2042

Phase 1Not yet recruiting

Esophageal Adenocarcinoma

NCT06748872

Clinical

Trials by Indication[1]

Esophageal Adenocarcinoma1 trial

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Not yet recruiting·MMediGene·Phase 1·NCT06748872·55 enrolled

Metastatic Melanoma1 trial

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01659151·17 enrolled

Lymphoma1 trial

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

Terminated·UUniversität Münster·Phase 2·NCT06912529·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lymphodepletion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lymphodepletion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lymphodepletion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MediGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMediGene

Lymphodepletion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2042

Trials by Indication[1]

Esophageal Adenocarcinoma1 trial

Metastatic Melanoma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News